HK Stock Market Move | Meikaman Siasun Robot & Automation (09615) fell over 9%, hitting a new low, with accumulated losses surpassing 1 billion over the past three years.
MechaMontage Robotics (09615) fell over 9%. The stock has declined for three consecutive days since its listing on September 1, reaching a new low of 88.3 Hong Kong dollars this morning.
Meikamada Siasun Robot & Automation (09615) fell over 9%, despite garnering 3,835 times the subscription and cornerstone investors accounting for more than 60%. The stock has struggled to avoid the fate of falling below its issue price, declining for three consecutive days since its listing on September 1. This morning, it hit a new low of HKD 88.3. As of the time of writing, it is down 9.47%, trading at HKD 88.95, with a turnover of HKD 34.91 million.
Meikamada is a supplier of intelligent Siasun Robot & Automation components. According to data from ZhiShi Consulting, based on revenue in 2025, the company ranks first in the global AI + 3D vision-guided general intelligent Siasun Robot & Automation component market, with a market share of approximately 22.1%. In terms of shipment volume, it also ranks first in the industry. In terms of performance, Meikamada's revenue is expected to grow from RMB 181 million in 2023 to RMB 389 million in 2025, but the company is still operating at a loss, with a cumulative net loss attributable to shareholders exceeding RMB 1 billion from 2023 to 2025.
Guotou Securities International believes that as a leading supplier of intelligent Siasun Robot & Automation components, the company is large in scale, widely applied, and continues to grow. However, it also cautions that the company is in a period of business and operational expansion, continuously increasing R&D investment while in a state of net loss; there is a high concentration of customers, and if demand from major partners declines or if partnership dynamics change, it may pose pressure on operational stability; the adaptation of technology and market acceptance during globalization expansion requires time to validate.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





